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Abstract: In degenerative adult onset ataxia (AOA), dystonic comorbidity is attributed to one disease
continuum. However, in early adult onset ataxia (EOA), the prevalence and pathogenesis of dystonic
comorbidity (EOAD+), are still unclear. In 80 EOA-patients, we determined the EOAD+-prevalence
in association with MRI-abnormalities. Subsequently, we explored underlying biological pathways
by genetic network and functional enrichment analysis. We checked pathway-outcomes in
specific EOAD+-genotypes by comparing results with non-specifically (in-silico-determined) shared
genes in up-to-date EOA, AOA and dystonia gene panels (that could concurrently cause ataxia
and dystonia). In the majority (65%) of EOA-patients, mild EOAD+-features concurred with
extra-cerebellar MRI abnormalities (at pons and/or basal-ganglia and/or thalamus (p = 0.001)).
Genetic network and functional enrichment analysis in EOAD+-genotypes indicated an association
with organelle- and cellular-component organization (important for energy production and signal
transduction). In non-specifically, in-silico-determined shared EOA, AOA and dystonia genes,
pathways were enriched for Krebs-cycle and fatty acid/lipid-metabolic processes. In frequently
occurring EOAD+-phenotypes, clinical, anatomical and biological pathway analyses reveal shared
pathophysiology between ataxia and dystonia, associated with cellular energy metabolism and
network signal transduction. Insight in the underlying pathophysiology of heterogeneous
EOAD+-phenotype-genotype relationships supports the rationale for testing with complete, up-to-date
movement disorder gene lists, instead of single EOA gene-panels.
Keywords: clinical genetics; early onset ataxia; dystonia; neurodevelopment; network analysis;
bioinformatics; ataxia; phenotype; child
1. Introduction
The diagnosis “early onset ataxia” refers to a group of rare, genetically inheritable diseases
with an estimated prevalence of 14.6 per 100,000 individuals, initiated before the 25th year of
life. These “ataxic syndromes” involve a heterogeneous group of underlying disorders that may
Diagnostics 2020, 10, 997; doi:10.3390/diagnostics10120997 www.mdpi.com/journal/diagnostics
Diagnostics 2020, 10, 997 2 of 17
phenotypically involve: (a) pure ataxic features; (b) predominant ataxic features in combination with
other comorbid movement disorder features; (c) mild ataxic features in combination with other primary
movement disorder features; (d) hardly discernible, disputable or even absent ataxic features, but with
an underlying diagnosis that is phenotypically described as ataxic in the Online Mendelian Inheritance
in Man (OMIM) database [1]. Depending on the age of the patient at disease presentation, patients
are categorized as ‘early onset ataxia’ (EOA, i.e., initiation before 25 years of age) or degenerative
‘adult onset ataxia’ (AOA, i.e., initiation after 25 years of age) [2]. Both disease groups are distinctly
different. Beside the age of onset, EOA and AOA groups are also different regarding: motor phenotype,
genes involved, genetic mode of inheritance, nature of associated genetic mutations and patterns of
disease progression.
Previous studies in patients with AOA have shown that the presence of ataxia with comorbid
dystonia (AOAD+) concerns a relatively frequently observed clinical phenotype in adulthood-onset
ataxias [3–5]. Depending on the underlying AOA gene mutation, the percentage of comorbid dystonia
(AOAD+) may vary between 0% up and 53% [5]. In AOA, the exact pathogenic mechanism for dystonic
comorbidity is not fully characterized, yet. Considering the degenerative nature of AOA disease courses,
one could assume that extra-cerebellar degeneration may be involved when disorders progress [5].
However, there are also AOA phenotypes that can initially present with dystonia instead of ataxia [6–8].
In a previous study, we have explored the converging biological pathways for dystonia and AOA
by determining the “shared genetics” between spinocerebellar ataxias (SCA)- and dystonia genes [3].
Forthcoming results indicated that there was a marked over-representation of shared genes involved
in GABA-ergic signalling and in neurodevelopment [3]. This implicates that, at least in addition to
extra-cerebellar neurodegenerative damage, aberrations in neurotransmission and developmental
regulated genes must be involved in the pathogenesis. In line with our previous findings in AOAD+,
we now aimed to explore the prevalence and underlying pathogenesis in paediatric and young adult
patients with EOA, with the underlying hypothesis that EOAD+ could be associated with abnormal
regulation of developmental genes and aberrations of neurotransmitter pathways as well. In mixed
dystonic and ataxic EOAD+-phenotypes, we anticipated that pathogenetic insight would contribute to
an insightful diagnostic approach.
In the present EOA study, we therefore aimed to elucidate the underlying key biological
pathways of dystonic comorbidity (EOAD+). We hypothesized that EOAD+-phenotypes could be
associated with: (1) extra-cerebellar neuro-degenerative alterations determinable by MRI; (2) identifiable
shared genetic/molecular pathways determinable by gene co-expression networks in specific EOAD+
genotypes; and (3) non-specifically (in-silico) determinable genetic/molecular pathways in shared genes
between AOA, EOA and dystonia gene panels, that may induce ataxia and dystonia in a concurrent
way. We hypothesized that if comorbid dystonia could be explained by neurodegenerative processes,
we would expect an association between the prevalence of comorbid dystonia and disease duration
and/or age of the patient, both in our cohort, as well as in literature. This could also implicate a
higher prevalence of comorbid dystonia in adult patients with AOA than in young patients with EOA.
When the comorbid occurrence of dystonia in EOA would rather be attributable to shared molecular
pathways and pathogenetic mechanisms, one would expect potentially corresponding results between
two different “genetic-network-analyses” groups: (1) in EOAD+ genotypes, with specifically identified
dystonic comorbidity; and (2) in non-specifically (in-silico-determined) shared genes in up-to-date
with EOA, AOA and dystonia gene panels, that could theoretically cause ataxia and dystonia in a
concurrent way [3].
In perspective of the above, we conducted this study in two parts: Part I: in a cohort of 80
EOA-patients, we investigated: (1) the prevalence of EOAD+, (2) the association between prevalent
EOAD+ comorbidity and disease duration and/or age of the patient, and (3) the association between
EOAD+ comorbidity and patterns of extra-cerebellar MRI abnormalities.
Part II: By genetic network and functional enrichment analysis, we investigated: (1) the shared
underlying pathways by determining co-expression networks in the identified EOAD+ genotypes;
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(2) the shared underlying pathways by determining co-expression networks in (in-silico-determined)
shared genes between AOA, EOA and dystonia gene lists (panels); and (3) comparative outcomes
between specifically identified EOAD+ genotypes (from our database) and non-specifically (in-silico
determined) shared genes in up-to-date EOA, AOA and dystonia gene lists (panels).
To the best of our knowledge, this is the first study providing a comprehensive approach to
explore the prevalence and pathogenesis of EOAD+.
2. Patients and Methods
The study was carried out following the rules of the Declaration of Helsinki of 1975 (revised in
2013), in accordance with the research and integrity codes of the University Medical Center Groningen
(UMCG). The Medical Ethical Committee of UMCG had approved the study (study no. UMCG research
register METc 2015/01053, METc approval date 11 July 2012). According to Dutch medical ethical law,
both parents and children older than 12 years provided informed consent whereas children younger
than 12 years of age provided informed assent for phenotypic assessment.
2.1. Phenotypic Assessment of Dystonic Comorbidity in a Cohort of EOA Patients
2.1.1. EOA Database
We included the video-recordings from a cohort of 80 EOA-patients that had visited the paediatric
neurology outpatient clinic at UMCG over the last 10 years. Included patients fulfilled the criteria
for “EOA”, implicating: symptomatic initiation of ataxia before the 25th year of life or an underlying
genetic diagnosis associated with a primary ataxic phenotype, as indicated by the OMIM database
(Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of Genetic Medicine,
Johns Hopkins University (Baltimore, MD, USA), 24 December 2016. WorldWide Web: http://omim.org/).
In accordance with international criteria for EOA databases, we included patients with congenital,
developmental, metabolic, degenerative, and/or unknown causes of ataxia starting before the 25th year
of life [9]. Patients were excluded when they exhibited iatrogenic causes, such as underlying infectious,
traumatic, intoxicative, cerebrovascular, para- and/or neoplastic pathology [10]. For the underlying
diagnosis, age of onset and disease duration of the included patients, see Table 1. The genetic diagnosis
of the patients was made using targeted gene panels for either early onset ataxia or dystonia.
Table 1. Early onset ataxia (EOA) patient information.




(Year) Gene Name *
Mutation
Type Neurological Diagnosis
1 0 14 14 RELN VUS cerebel cort dyspl, hypopl pons
2 0 17 17 LAMA1A MM Poretti Boltzhausen syndrome
3 0 13 13 - - Dandy Walker malformation
4 0 14 14 Unknown - Unknown
5 0 9 9 SOX 10 MM Shah-Waardenburg syndrome
6 0 22 22 CHD7 MM CHARGE Syndrome
7 7 6 14 Unknown - Unknown
8 0 7 7 KIAA0586 MM Joubert Syndrome 23
9 11 0 11 - - Cediak Higashi
10 0 12 12 SPTBN2 Del, MM SCA5
11 3 7 11 Unknown - Unknown
12 2 8 10 FXN GAArepeat Friedreich’s ataxia
13 0 10 10 CTNNB1-gen MM AD MR 19
14 0 8 9 KCNC3 MM SCA13
15 0 9 10 Unknown - Unknown
16 1 7 8 HSD17B10 MM MHBD-deficiency
17 4 5 9 FXN GAA repeat Friedreich’s ataxia
18 3 4 7 EBF3 mutation MM HADDS syndrome
19 4 1 5 FXN GAA repeat Friedreich’s ataxia
20 0 0 1 INPPE5 MM Joubert syndrome type 1
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Table 1. Cont.




(Year) Gene Name *
Mutation
Type Neurological Diagnosis
21 14 1 16 Unknown - Unknown
22 5 6 11 GOSR2 MM Northsea progr myocl
23 2 4 6 Unknown - Unknown
24 0 5 5 Unknown - Unknown
25 2 8 10 Unknown - Unknown
26 13 2 15 CACNA1A MM Episodic Ataxia type 2
27 4 7 11 FXN GAA repeat Friedreich’s ataxia
28 2 5 7 KCND3 MM SCA19
29 6 8 14 CACNA1A MM Episodic Ataxia type 2
30 1 2 3 CAMTA1 MM CAMTA1
31 0 13 13 Unknown - Unknown
32 2 7 9 TITF1 MM Benign Hereditary Chorea
33 4 2 6 ZMYND11 MM AD, MR type 30
34 1 12 13 ITPR1 MM SCA 29
35 3 9 12 ITPR1 MM SCA29
36 4 11 15 ITPR1 MM SCA29
37 12 0 12 Unknown - Unknown
38 1 1 2 Unknown - Unknown
39 6 3 9 SPTBN2 Del, MM SCA5
40 1 7 8 ATP1A3 MM RDP-AHC-Atax
41 2 5 8 ATP1A3 MM AHC
42 9 23 32 TTPA MM AVED
43 4 11 15 FXN GAA repeat Friedreich’s Ataxia
44 12 3 15 NPC MM Niemann Pick
45 12 22 34 TTPA MM AVED
46 1 25 26 T8993G MM NARP
47 16 11 28 TTPA MM AVED
48 5 11 16 HTT CAG repeat Juvenile Huntington
49 1 18 19 ATM MM Ataxia Telangiectasia
50 5 3 8 FXN GAA repeat Friedreich’s Ataxia
51 0 5 5 - - cong malf fossa pos
52 11 6 18 mtDNA MM Kearns Sayre Syndrome
53 10 2 13 FXN GAA repeat Friedreich’s ataxia
54 14 3 18 SPG-11 MM HSP
55 1 17 18 GOSR2 MM Northsea progr myocl
56 2 23 25 GOSR2 MM Northsea progr myocl
57 0 6 6 Unknown - Unknown
58 3 13 16 CACNA1A CAG repeat Episodic Ataxia type 1
59 0 15 15 KIAA0586 MM Joubert Syndrome 23
60 3 3 6 GOSR2 MM Northsea progr myocl
61 3 13 16 CACNA1A CAG repeat Episodic Ataxia type 1
62 13 9 22 TTPA MM AVED
63 2 0 3 GOSR2 MM Northsea progr myocl
64 2 18 20 GOSR2 MM Northsea progr myocl
65 2 1 3 ALDH3A2 MM SjogrenLarsson
66 8 5 13 SPG11 MM Spastic paraplegia 11
67 6 13 19 FXN GAA repeat Friedreich’s Ataxia
68 7 14 21 FXN GAA repeat Friedreich’s Ataxia
69 9 13 22 FXN GAA repeat Friedreich’s Ataxia
70 6 10 17 FXN GAA repeat Friedreich’s Ataxia
71 4 10 14 FXN GAA repeat Friedreich’s Ataxia
72 5 7 12 FXN GAA repeat Friedreich’s Ataxia
73 2 9 11 TUBB2A MM CDCBM5
74 1 1 3 ATP1A3 MM FIPWE
75 1 11 12 CACNA1A CAG repeat Episodic Ataxia type 2
76 7 5 12 ATXN7 CAG repeat SCA7
77 15 0 16 SLC2A1 gen MM Glut-1 def
78 0 3 3 Unknown - Unknown
79 5 4 9 FXN GAA repeat Friedreich’s ataxia
80 6 10 16 FXN GAA repeat Friedreich’s Ataxia
Gene name * = gene name, mutations are specified in the Suppl. Table S1; cerebel cort dyspl = cerebellar
cortical hypoplasia; hypopl = hypolasia; VUS = variant of unknown significance; MM = missense mutation;
MHBD = 2-methyl-3-hydroxybutyryl-CoA-hydrogenase deficiency, HADDS = hypotonie; ataxie and delayed development
syndrome; RDP-AHC-Atax = disease continuum of rapid onset parkinsonism (RDP); alternating hemiplegia of childhood
(AHC); ataxia AVED = Ataxia with isolated vitamin E deficiency; NARP = neuropathy; ataxia and retinitis pigmentosa;
cong malf fossa pos = congenital malformation fossa posterior; CDCBM5 = cortical dysplasia, complex, with other brain
malformations; FIPWE = fever-induced paroxysmal weakness and encephalopathy.
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2.1.2. Phenotypic Assessment
In accordance with previously described methodology [1], we included videotaped SARA (scale for
assessment and rating of ataxia [11]) or ICARS (international cooperative ataxia rating scale [12])
performances, that had been video-taped at the outpatient clinic for patient surveillance reasons.
Both scales have been shown to capture paediatric ataxic movement disorder features in a similarly
reliable way [13,14]. Furthermore, SARA has been shown to capture other phenotypic features of
comorbid movement disorders, as well [15]. We included previously video-taped motor performances
of 80 patients fulfilling the criteria of EOA. When patients had been videotaped on several occasions,
we systematically included the motor performances that had been performed at the shortest disease
duration (i.e., youngest age) of the patient. This provided us the opportunity to assess the motor
phenotypes at a relatively early, mostly ambulant disease stage, with the smallest chance of any potential
ceiling effects (for instance by the inability to walk or stand). Two paediatric neurologists, specialized
in movement disorders, independently phenotyped the videotapes. In accordance with previously
described methods, the paediatric neurologists indicated the observed movement disorder features
and estimated severity (Suppl. Figure S1 [1]). The assessors individually captured the “print screens”
including the time frames from the video-fragments at which they observed dystonic posturing.
Patients were assigned to the EOAD+ study group when both assessors had indicated that comorbid
dystonia was present. Patients were assigned to the EOAD− control group, when both assessors had
indicated that comorbid dystonia was absent. In the remaining patients (neither belonging to the
EOAD+, nor to the EOAD− control group), both assessors explained their phenotypic choice in a
separate after-session by play-back at the indicated time frames from the “print screens”.
To allow subsequent statistical comparison on a sufficient number of genes in the study- and
control-group, we had to supplement the EOAD− (control) group with additional ataxia genes that
were reported without comorbid dystonia, in literature (PubMed and OMIM). For genes included in
the EOAD+ study and EOAD− control group, see Suppl. Table S2.
2.1.3. MRI Abnormalities in EOAD+ and EOAD− Subgroups
We subdivided the local cohort of 80 EOA patients into phenotypes with and without comorbid dystonia
(i.e., the EOAD+ study-group and EOAD− control group, respectively). In both groups, we subsequently
associated the underlying genotypes with the corresponding brain abnormalities reported in literature
(PubMed and OMIM databases). We characterized cerebral MRI abnormalities in EOAD+ and EOAD−
groups for: (1) the neuro-anatomical location and (2) the nature of cerebral abnormalities.
2.2. Network Analysis
2.2.1. Pathway and Network Analysis on the Study-Group (EOAD+) and Control-Group (EOAD−)
In the EOAD+ study group and EOAD− control group, we related the associated genotypes with the
patterns of MRI abnormalities. Subsequently, we performed a pathway and network analysis to evaluate
the underlying biological processes and molecular pathways associated with the characterized genetic
subgroups. For this purpose, we used the co-expression tool GeneNetwork (www.genenetwork.nl) to
generate gene networks using the gene set enrichment feature. The pathway enrichment prediction of
the clusters in the disease-specific networks was also performed by GeneNetwork and only the top
significant gene ontology (GO) biological pathways were considered. In order to obtain sufficient
genes for statistical analysis of the EAOD− control group, we added ataxia genes that were not reported
with comorbid dystonia in literature (ABHD12; IFRD1; KIAA0226; PHYH; TDP1; VWA3B; GTF2H5;
FLVCR1; ACO2; HSD17B4; DNAJC3 gene mutations; PubMed and OMIM).
2.2.2. Pathway and Network Analysis in EOA, AOA and Dystonia Genes
In order to compare our specific pathway and network results (obtained ad IIa), with the
non-specific outcomes derived from (in-silico-determined) shared genes between complete, up-to-date
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clinically applied gene panels (that could concurrently induce ataxia and dystonia), we compiled the
most recent disease associated gene lists (used for clinical genetic diagnostics at the Department of
Genetics of the UMCG, Groningen, the Netherlands), including EOA (n = 152 genes), AOA (n = 80 genes)
and dystonia (n = 100 genes); see Suppl. Table S3. The biological pathways that were enriched in
the EOA, AOA and dystonia genes were identified by the Toppfun feature of ToppGene Suite
(https://toppgene.cchmc.org). The GO biological pathways were considered significant up to p-values
0.005 (Bonferroni, e.g., corrected for multiple testing). In accordance with previously published
methods [3], we used GeneNetwork (www.genenetwork.nl) a co-expression tool by integrating
31,499 public RNA-seq samples [16] to generate the EOA, AOA and dystonia gene co-expression
networks using the gene set enrichment feature. The pathway enrichment prediction of the clusters
in the disease-specific networks was also performed by GeneNetwork and only the top significant
GO biological pathways were considered for this work. GO biological pathways were considered
significant up to p-values of 5 × 10−5.
2.2.3. Comparison of Shared Pathways between EOAD+ and EOA, AOA and Dystonia Gene Panels
(2a versus 2b)
Finally, we compared the underlying shared pathways between: (1) specific EOAD+ genotypes
that were phenotyped with comorbid dystonia; and (2) (in silico determined) non-specifically shared
pathways, derived from up-to-date EOA, and AOA, dystonia gene lists panels, that could concurrently
induce ataxia and dystonia. For this purpose, we used the EOA, and AOA, dystonia gene lists that are
included in the gene panels at the University Medical Center Groningen.
2.3. Statistics
The reliability of the agreement between the observers, was indicated by Cohen’s kappa. Results
were interpreted in accordance with Landis and Koch as: poor (k < 0); slight (k 0–0.20); fair (k 0.21–0.40);
moderate (k 0.41–0.60); substantial (k 0.61–0.80) and almost perfect (k 0.81–1.00) [17]. We determined
normality of disease duration and age of the patient by Shapiro Wilk test. We associated the presence
of comorbid dystonia with both disease duration (at the time of the included video-recording) and
age of the patient by Mann–Whitney U test. The significance level was set at α = 0.05. Statistical
analysis was performed using IBM SPSS statistics 23.0, Statistics for Windows, Version 23.0. Armonk,
NY, USA: IBM Corp. In the study and control group, we combined and compared specific groups of
genes according to the associated MRI patterns, using the Fisher-exact test.
3. Results
3.1. Prevalence of Comorbid Dystonia in 80 Patients with EOA
3.1.1. Clinical Characteristics of Included EOA-Patients
For the underlying diagnosis, age of onset, disease duration of the included patients, see Table 1.
The disease duration and age of the patient (at video-assessment) were not normally distributed
(Shapiro Wilk test (p = 0.001)). In 84% (67/80) EOA patients, the underlying association with the disease
symptom ataxia was confirmed by genetic, metabolic and/or radiologic findings. In 78/80 (98%) of the
recorded EOA-patients, either one of the two observers had recognized the presence of the symptom
ataxia. In 76/80 (95%) of the recorded EOA-patients, both observers had recognized the presence of
the symptom ataxia. The two patients in whom none of the observers had recognized ataxia, were
diagnosed with an ATP1A3 and TUBB2A mutation, respectively. Both patients had been described
with ataxic features in the records of the outpatient clinic, but these features could apparently not
be identified during the off-line video-assessment of the specific SARA video-recording. For rough
scoring data and specific gene mutations, see Suppl. Table S1. Scored dystonic comorbidity is indicated
in Suppl. Table S4a.
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3.1.2. Evaluation of Comorbid Dystonia
In 52/80 (65%) of the EOA-patients, comorbid presence of dystonia was indicated by both observers,
characterized by “comorbid dystonia”. In 11/80 (14%) of the EOA-patients, the symptom dystonia was
assessed by one observer and in 17/80 (21%) dystonia was assessed as absent by both observers. In 3/52
(6%) of the EOA-patients with comorbid dystonia (TTPA, ATP1A3 and TUBB2A gene mutations),
both observers had indicated that dystonia was severely present and that dystonia was presented as
the main phenotype. In two of these patients (ATP1A3 and TUBB2A gene mutations), ataxia had not
been identified. In the other 49/52 (94%) of EOA-patients with comorbid dystonia, both observers
had indicated that dystonia was (mostly mildly) present and that dystonia concerned the secondary
phenotype. Either presence, or absence of comorbid dystonia was not significantly associated with
EOA disease duration and/or age of the patient (p = 0.645 and p = 0.103, respectively; Mann–Whitney
U test), see Suppl. Table S4b. In the patients with successive video-recordings, dystonic features did
not longitudinally change from mild to severe (data not shown).
3.1.3. Association between Phenotype and Underlying Etiology
EOAD+ phenotypes were associated with genetic mutations (n = 41; 79%), congenital malformations of
the fossa posterior (n = 2; 4%) and unknown causes (n = 9; 17%), see Table 2a. The EOA phenotypes without
comorbid dystonia (28/80; 35%) were associated with genetic mutations (13; 81%); congenital malformations
of the fossa posterior (n = 1; 6%), and unknown causes (n = 2; 13%), see Table 2b. The diagnoses Friedreich’s
ataxia, North Sea progressive myoclonus epilepsy, episodic ataxia type 2 and congenital malformations of
the fossa posterior were both associated with presence and with absence of comorbid dystonia (EOAD+ and
EOAD− phenotypes); see Table 2a,b, respectively.
Table 2. EOA gene mutations with (a) and respectively without comorbid dystonia (b).
a. with comorbid dystonia
Gene mutation
TUBB2A (n = 1) ATXN7 (n = 1) LAMA1A (n = 1)
FTX (n = 9) KCNC3 (n = 1) CHD7 (n = 1)
INPPE5 (n = 1) ATM (n = 1) LYST (n = 1)
ATP1A3 (n = 3) CAMTA1 (n = 1) HSD17B10 (n = 1)
TTPA (n = 3) NARP (n = 1) HADDS (n = 1)
CACNA1A (n = 3) ZMYND11 (n = 1) CTNNB1 (n = 1)
GOSR2 (n = 2) ALDH3A2 (n = 1) HTT (n = 1)
SPTBN2 (n = 2) TITF1 (n = 1) SPG11 (n = 1)




KCND3 (n = 1) CACNA1A (n = 2)
FTX (n = 3) SPG11 (n = 1)
GOSR2 (n = 3) ** unknown (n = 3)
ITPR1 (n = 3)
Legends: * unknown (n = 12) = unknown/absent gene mutation in association with malformation of fossa posterior
(n = 2); LYST = Cediak Higashi syndrome (n = 1); no clinical diagnosis (n = 9); ** unknown (n=3) = unknown/absent
gene mutation in association with malformation of fossa posterior (n = 1); no clinical diagnosis (n = 2). The gene
mutations CACNA1A, FTX and GOSR2 were present in clinical cases with and without comorbid dystonia. Cases with
a congenital malformation of the fossa posterior were both associated with and without comorbid dystonia.
3.1.4. Reliability of Agreement between the Observers
The reliability of the agreement between the observers, was indicated by Cohen’s kappa of 0.668
(p < 0.001). The kappa value was interpreted as sufficient to good in accordance with Landis and
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Koch [17]. In 69/80 (86%) patients, there was full agreement between the two observers on the presence
or absence of comorbid dystonia. In 11/80 (14%) patients, the presence of comorbid dystonia was only
indicated by one observer. In these 11 patients, the other observer had explained that the dystonic-like
features were recognized, but that these features could not be discriminated from dystonic-like features
due to physiologic immaturity of the central nervous system. These cases were therefore excluded
from the subsequent analysis of EOAD+ and the EOAD− groups.
3.1.5. EOAD+ and EOAD− Groups and Associated MRI Abnormalities
In the investigated cohort, there were 25 genotypes in association with EOAD+, 6 genotypes in
association with EOAD− and 4 genotypes in association with both EOAD+ and EOAD−. In total,
only 2 genotypes were included in the EOAD-control group. We, therefore, supplemented the EOAD-
control group with ataxia genotypes that were not reported with comorbid dystonia in literature
(including ABHD12; IFRD1; KIAA0226; PHYH; TDP1; VWA3B; GTF2H5; FLVCR1; ACO2; HSD17B4;
DNAJC3 gene mutations; PubMed and OMIM). For the included EOAD+ and EOAD− groups and
associated MRI abnormalities, see Suppl. Table S2. Reported MRI abnormalities were subdivided
into hypoplasia; atrophy; and specifically described damage (see also Suppl. Table S2). Associating
reported MRI abnormalities with EOAD+ and EOAD− phenotypes, revealed a significant association
between EOAD+ phenotypes and abnormalities at the pons and/or basal ganglia and/or thalamus
(p = 0.001), see Suppl. Table S5. Comparing the division of white and grey matter damage between
EOAD+ versus EOAD− groups, did not reveal statistical differences, see Suppl. Table S6.
3.2. Pathway and Network Analysis
3.2.1. EOAD+ Genotypes
In the EOAD+ gene group, pathway analysis revealed the strongest enrichment for GO biological
processes involved in organelle organization (p = 8.853 × 10−17), and additionally in cellular component
organization or biogenesis (p = 2.315 × 10−12), chromosome organization (p = 7.158 × 10−8) and
cytoskeleton organization (p = 3.441 × 10−7). These are cellular processes resulting in the assembly,
(re-) arrangement or disassembly of organelles, cellular components, chromosomes and cytoskeleton in
a cell. For pathway and network analysis in EOAD+ and EOAD− groups in association with allocated
MRI damage, see Table 3.
Table 3. Top biological pathways in Early Onset Ataxia and Dystonia (EOAD+) and (EOAD−).
Subgroup Most Significant Pathways p-Value
EOA, Dystonia + (EOAD+)
1. organelle organization 8.853 × 10−17
2. cellular component organization or biogenesis 2.315 × 10−12
3. cellular component organization 1.767 × 10−11
4. chromosome organization 7.158 × 10−8
5. cytoskeleton organization 3.441 × 10−7
EOA, Dystonia − (EOAD−)
1. small molecule metabolic process 1.091 × 10−17
2. cellular lipid metabolic process 2.773 × 10−15
3. lipid metabolic process 2.866 × 10−15
4. cellular lipid catabolic process 6.840 × 10−15
5. carboxylic acid metabolic process 1.376 × 10−14
EOA, White Matter
damage + (EOAW+)
1. organelle organization 4.102 × 10−8
2. cellular component organization 6.759 × 10−8
3. cellular component organization or biogenesis 8.330 × 10−8
4. regulation of organelle organization 4.108 × 10−7
5. regulation of cellular component organization 6.354 × 10−6
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Table 3. Cont.
Subgroup Most Significant Pathways p-Value
EOA, White matter
damage − (EOAW−)
1. ribonucleoprotein complex biogenesis 1.897 × 10−6
2. cellular nitrogen compound metabolic process 3.662 × 10−6
3. ribosome biogenesis 8.758 × 10−6
4. cellular component organization or biogenesis 9.220 × 10−5 *
5. RNA processing 1.389 × 10−4 *
EOA, extracerebellar
damage + (EOAX+)
1. carboxylic acid metabolic process 5.703 × 10−10
2. oxoacid metabolic process 9.228 × 10−9
3. organic acid metabolic process 1.635 × 10−8
4. cellular lipid catabolic process 1.742 × 10−6
5. vacuolar transport 3.896 × 10−6
EOA, extracerebellar
damage − (EOAX−)
1. RNA metabolic process 4.933 × 10−16
2. mRNA metabolic process 1.716 × 10−14
3. nucleic acid metabolic process 2.453 × 10−13
4. gene expression 9.775 × 10−13
5. mRNA processing 5.158 × 10−12
EOA, cerebellar
damage + (EOAC+)
1. cellular component organization 9.435 × 10−11
2. cellular component organization or biogenesis 1.286 × 10−10
3. organelle organization 9.573 × 10−10
4. cellular localization 3.517 × 10−7
5. vacuolar transport 3.177 × 10−6
EOA, cerebellar




1. organelle organization 9.603 × 10−15
2. cellular component organization or biogenesis 3.714 × 10−13
3. cellular component organization 1.062 × 10−12
4. cellular localization 2.485 × 10−8
5. microtubule-based process 1.631 × 10−7
+ = comorbid sign is present; − = comorbid sign is absent; EOAD = EOA and comorbid dystonia; EOAW = EOA and
white matter damage; EOAX = EOA and extra-cerebellar damage; EOAC = EOA and cerebellar damage;
EOADW = EOA, dystonia and white matter damage. * Not significant. Statistical significance for pathway
analysis: p < 5 × 10−5.
3.2.2. Shared Genes in EOA, AOA and Dystonia Gene-Lists (Panels)
In EAO, AOA and dystonia gene lists (Suppl. Table S3), we identified 54 shared genes between
EAO and AOA, 13 between EAO and dystonia, and 8 between AOA and dystonia (Suppl. Figure S2 and
Suppl. Table S7). The latter 8 genes were also shared between EAO and dystonia (i.e., shared between
EOA, AOA and dystonia). These gene mutations included: ATP1A3 (associated with the expanding
phenotypic spectrum of alternating hemiplegia of childhood, rapid-onset dystonia-parkinsonism,
CAPOS and FIPWE) [18], POLG (mitochondrial depletion syndrome), NPC1 (Niemann–Pick disease,
type C1), TUBB4A (DYT4), MTTP (abetalipoproteinemia), SPG7 –(spastic paraplegia 7) and SLC2A1
(GLUT1 deficiency syndrome). Two of these genes, NPC1 and MTTP, are associated with plasma
lipoprotein particle organization and cholesterol homeostasis.
3.2.3. Pathway Analysis in EOA, AOA and Dystonia Gene Lists (Panels)
We identified 90 significant GO biological pathways in EOA, 39 in AOA and 132 in dystonia
genes (Suppl. Tables S8–S10). Of these pathways, 8 were shared between the three disorders,
including cation- and ion transport, cation- and ion transmembrane transport, inorganic cation- and
ion transmembrane transport, transmembrane transport, and locomotion pointing to an important
role of cellular communication via synaptic transmission and movement in the underlying shared
biology. For EOA, the most enriched GO pathways were locomotion, neurogenesis, myelination,
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and ion transport. For AOA, similar to EOA, pathways were associated with locomotion, ion- and
trans-membrane transport, chemical- and synaptic transmission, and anterograde trans-synaptic
signaling. For dystonia, pathways such as cellular respiration, oxidation-reduction process, respiratory-
and electron transport chain, mitochondrial respiratory chain complex assembly and mitochondrion
organization were identified. Overall, EOA and AOA are more similar in their underlying biological
pathways compared to either one of them with dystonia, whereas dystonia shared only a few (n = 5)
unique biological pathways with EOA but not with AOA.
3.2.4. Network Analysis in EOA, AOA, Dystonia
The EOA, AOA, dystonia networks comprised of 7, 3, and 4 clusters, respectively (Suppl. Figures S3–S5).
We identified 472 shared genes between the three networks (Figure 1A and Supp. Table S11). The networks
of EOA-AOA showed most overlap in genes (n = 1210), compared to EOA-dystonia (n = 1004) and
AOA-dystonia (n = 500). The 472 shared genes between the three networks were enriched for GO pathways
(top 10 ToppGene) involved in carboxylic acid—and organic acid metabolic process, fatty acid—and lipid
metabolic process, and organic—and carboxylic acid catabolic process (Figure 1B). The 532 uniquely shared
genes between EOA and dystonia were enriched for GO pathways involved in cellular respiration,
drug metabolic process, ATP biosynthetic process, respiratory electron chain transport and purine
ribonucleoside triphosphate biosynthetic process (Suppl. Table S12), whereas the 28 uniquely shared
genes between AOA and dystonia were enriched in GO pathways involved in the release of calcium into
the cytosol and calcium ion transport (Suppl. Table S13).
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Figure 1. Shared genes and pathways between EAO, AOA and dystonia networks. Legend: (A) Venn
diagram plot showing 472 common genes between EOA, AOA and dystonia. The gene networks
of EOA—dystonia (n = 1004 (532 + 472)) reveal more overlap than the gene networks between
AOA—dystonia (n = 500 (28 + 472)), suggesting that the gene networks of EOA is more similar to
the dystonia network compared to the network of AOA—dystonia. (B) Top 10 of the most enriched
pathways (top 10 ToppGene) of the common genes between EOA, AOA and dystonia. The most
enriched pathways involved are involved in carboxylic acid—and organic acid metabolic process and
fatty acid—and lipid metabolic process.
4. Discussion
To the best of our knowledge, this is the first study targeting at the underlying biological pathways
in patien s with EOA with c morbid dystonia (EOAD+-pheno ypes). In the majority of EOA-patients,
we observed only mildly dystonic features. The prevalence of dysto ic comorbidity (65%) was
apparently higher than previously reported prevalence in AOA-pati ts (0% to 53%, depending
on the genotype) [5]. In addition to MRI abnormalities at the cerebellum, EOAD+-phenotypes
revealed a strong association with MRI abnormalities at the basal ganglia and/or thalamus and/or pons
(implicating disturbed signaling somewhere in the anatomical cortico-basal-ganglia-ponto-cerebellar
network [19,20]). There was no association between the presence or absence of comorbid dystonia
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and EOA disease duration and/or age of the patient, implicating that other factors than ongoing
neuro-degeneration are likely to play a role in the pathogenesis of comorbid dystonia. In our
EOAD+-study group, pathway and molecular co-expression network analysis indicated an underlying
association with organelle and cellular organization (underlying energy production and signal
transduction). As such pathways are not implicated in EOA alone, these findings are in line with
previous studies demonstrating a pathophysiologic role for cytoskeletal reorganization in the underlying
biology of dystonia [21]. Comparing these results with (in-silico-determined) network analysis in
shared EOA, AOA and dystonia gene lists (panels), showed enrichment for Krebs-cycle (tricarboxylic
acid cycle (TCA)) and fatty acid/lipid metabolic process, underlying the concept of hampered energy
production and signal transduction. From these data, we conclude that both specifically (EOAD+) and
non-specifically (in silico determined) shared pathways and networks analyses implicate an underlying
role for cellular energy production and network signal transduction in the pathogenesis of EOA with
comorbid dystonia. This may have implications for genetic testing. Instead of testing with a single
EOA gene panel, one may consider using Whole Exome Sequencing (WES), a complete movement
disorder panel and copy number variation analysis, whereas diagnostics by Whole Genome Sequencing
(WGS) may have a wider application, in the future. Previous studies in neuro-degenerative AOA
disorders, have implicated that the comorbid presence of dystonia should be regarded as an expression
of the same disease continuum [4,22,23]. Conversely, in adult patients, dystonic symptoms have also
been associated with cerebellar pathology [24,25] and cerebellar symptoms, including action induced
tremors [26], eye blink conditioning [27] and saccadic adaption [28]. However, in the presently studied
cohort of 80 relatively young EOA patients, we observed comorbid dystonia (EOAD+) in the majority
(65%) of patients. This EOAD+ subgroup revealed a large heterogeneity in genotype-phenotype
relationships, reflected by: (1) identical genetic mutations that were associated with EOAD+ and also
with EOAD− phenotypes (in different patients), (2) absence of EOAD+ features in genotypes that
have been identified with comorbid dystonia in literature and (3) presence of EOAD+ features in EOA
genotypes that have not been reported with comorbid dystonic features, before. As expected, we
observed that MRI abnormalities of the basal ganglia and/or pons and/or thalamus were associated
with the EOAD+ phenotype. In addition to the well-known association between abnormalities at the
basal ganglia and thalamus with dystonia, the pedunculo-pontine tegmental nucleus (PPTg) at the
pons has been shown to connect between the basal ganglia and cerebellar nuclei and thalamus [29]
implicating that hampered signaling in the anatomical cortico-basal-ganglia-ponto-cerebellar network
may be involved [19,20].
Comparing the dystonic prevalence in “early disease onset” EOA (EOAD+; 65%) with previously
reported “adult disease onset” AOA (AOAD+; 0% to 53% depending on the genotype) [5,30–33],
reveals a higher prevalence in the first group. This could be theoretically attributed to several factors.
First, it is well known that dystonic-like features may physiologically appear in young children, due to
the incomplete maturation of the central nervous system [34,35]. However, in EOA we observed no
association between EOAD+ and young age and/or shorter disease duration. Furthermore, the majority
of patients were older than 10 years of age. After this age, physiologic dystonic-like features have mostly
disappeared [34,35] and, finally, we had excluded all patients with doubtful minor developmental
dystonic-like features from the study. Second, one could attribute the higher prevalence of dystonic
comorbidity in EOA than in AOA to more advanced extra-cerebellar neuro-degeneration. However,
considering the younger age of the EOA patients and the inclusion of the firstly recorded movement
disorder performances, this appears unlikely, as well. Another, and much more likely explanation is
provided by our non-specific, in silico pathway and network analysis, performed on shared genes
between up-to-date EOA, AOA and dystonia gene panels. Comparing gene network similarities,
revealed about twice as much overlapping gene networks between EAO- and dystonia-genes than
between AOA- and dystonia-genes. From this molecular genetic perspective, it could be derived that
dystonic comorbidity is also about twice as likely to concur with EOA than with AOA.
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In the present study, we hypothesized that the underlying genetic mechanisms for EOAD+ could
both involve: (1) shared pathways inducing a specific EOAD+ phenotype, and/or (2) non-specifically
shared pathways by genes that may be concurrently expressed in EOA, AOA and dystonia, inducing
comorbid features. Investigating shared pathways in the specific EOAD+ group, revealed an association
with organelle- and cellular- organization. Until now, these pathways have not been described in
EOAD+ before. Mitochondria are important organelles generating most of the cellular energy by the
TCA (Krebs cycle). Pathways of cellular organizations are involved in the axonal cytoskeleton providing
the basis for axonal transport and network signaling. This may imply that novel EOAD+-phenotype
related gene mutations could be found in association with these molecular pathways.
By investigating the non-specifically shared genes and pathways between EOA and AOA genes,
we identified quite similar pathway enrichment for the EAO and AOA gene list, that was different
from dystonia. The top biological pathways observed for EAO and AOA were involved in locomotion
and neurogenesis. These biological pathways have also been implicated in the pathogenesis of ataxia
syndromes [36,37]. The top biological pathways observed for dystonia were involved in cellular
respiration and metabolism. Additionally, studies reported changes in cellular—and /or mitochondrial
respiration in dystonia [38,39], supporting the validity of our in silico genetic analysis. Not surprisingly,
none of the top pathways underlying either ataxia or dystonia were shared between EAO, AOA and
dystonia. In fact, several pathways involved in cation and ion membrane transport were enriched in
the common genes, pointing to an important role for neuronal communication that is also consistent
with prior knowledge on the pathology of these mixed disorders [38,40,41]. Furthermore, we observed
that carboxylic acid—and organic acid metabolic and catalytic processes were enriched in the common
genes, pointing out to the tricarboxylic acid cycle (TCA), or Krebs cycle. The TCA cycle, is essential for
mitochondrial ATP production and is fueled by fatty-acid–oxidation. Furthermore, the TCA cycle is
crucial for the synthesis of gamma aminobutyric acid (GABA), the main neurotransmitter of Purkinje
cells (PCs). In dystonic syndromes, it is reported that PCs are dysfunctional and in ataxic syndromes
PCs are often also degenerative [25,42]. Of note, one of the clusters of the AOA network was enriched
for genes involved in gamma-aminobutyric acid (GABA) signaling pathway, and altered GABA-ergic
signaling has also been reported to play a role in patients with cervical dystonia [43]. Finally, cellular
energy failure has been implicated in the pathogenesis of cerebral demyelination. Whether preferential
loss of Myelin-associated glycoprotein is a feature of primary mitochondrial disorders [44], or due to
mutations in nuclear genes is still unclear [45].
The enrichment for lipid and fatty acid homeostasis in the shared genes (Figure 1B) of the
disease specific molecular networks further support the role for development of the central nervous
system in the pathology of these disorders. Cholesterol is an essential lipid for mammalian
cells, and is necessary for the numerous formations of efficient synapses, which stems from de
novo synthesis [46]. Whereas fatty acids and their metabolites are required for normal brain
development and the activation of gene transcription regulating long-chain polyunsaturated fatty
acids formation. Many neurodegenerative diseases are associated with disrupted lipid- and cholesterol
homeostasis, including such Niemann Pick type C disease, Smith Lemli Opitz, and SCA3 [46,47].
In neurodegenerative mouse models for spinocerebellar ataxia, it was shown that impaired cholesterol
metabolism reduces the Purkinje cell number and induces motor coordination deficits [48]. Furthermore,
it has been shown that that the cerebellum can modulate the basal ganglia activity [19,20] by input from
the neurologic cerebello-thalamo-basal ganglia anatomical pathway [49]. In the central nervous system,
oligodendrocytes generate multiple layers of myelin around axons of the central nervous system to
enable fast and efficient nerve conduction. Until recently, saltatory nerve conduction was considered
the only purpose of myelin, but myelinating oligodendrocytes can also provide metabolic support
to neurons, and regulate ion and water homeostasis by adapting to activity-dependent neuronal
signals [50]. Mutations in very long chain fatty acid elongase 4 and 5 (Elovl4 and ElovL5) are reported
to cause spinocerebellar ataxia [51–53] and accumulation of the branched-chain acid fatty acid was
reported to be associated with Refsum disease caused by mutations in Phytanic acid alpha-oxidation
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(in AOA gene panel) [54]. Additionally, MECR mutations cause a mitochondrial fatty-acid synthesis
disorder and is characterized by a childhood-onset dystonia [55]. Altogether, these crucial biological
pathways may thus support the hypothesis that they can concurrently underlie the initiation of ataxia
and dystonia [4]. Nevertheless, this does not necessarily implicate that these pathways also play
a specifically causative role in the pathogenesis of comorbid dystonia. However, investigating the
pathway and network analysis in the specifically phenotyped EOAD+ group, reveals a similar role for
organelle and cellular organization in dystonic comorbidity. Although not identical, both specifically
and non-specifically shared pathways may thus implicate an association with hampered cellular energy
production and network signal transduction.
We are aware of some weaknesses to this study. In the first place, the presently studied EOA
gene panel cannot be considered complete, since new genes are being, and will be added in the future.
Furthermore, by using an EOA database from a single center, we cannot exclude local influences on the
outcome data. For instance, we noticed that some of the EOAD+ genes are not associated with dystonia
in literature, and vice versa. However, considering the fact that (1) EOA is a rare disorder, (2) we
were able to include a considerable cohort of 80 EOA patients, (3) the identified EOAD+ phenotypes
were linked with extra-cerebellar MRI alterations at the basal-ganglia-ponto-thalamic network, and (4)
pathway- and network-analyses in both specific EOAD+ phenotypes and in silico determined shared
genes reflected similarly underlying biological processes, we would suggest that the present results
can be interpreted as indicative. Hopefully, future collaboration with European and even world-wide
based ataxia databases will elucidate this.
In summary, in a local cohort of 80 EOA-patients, we observed dystonic comorbidity in the majority
of patients. Exploration of the underlying clinical, anatomical and biological pathways revealed shared
pathophysiology, despite genotype-phenotype heterogeneity. Both patient specific (in EOAD+) and
non-specific (in silico determined) pathway- and network-analyses implicated associated biological
pathways involved in organelle and cellular organization, respectively in TCA cycle processes and
lipid and fatty-acid homeostasis. Both outcomes suggest that hampered energy production and
network signal transduction may play an underlying role in the pathophysiology of ataxia with
comorbid dystonia.
These findings may have important implications for the diagnostic approach in mixed “EOA”
comorbid dystonia movement disorders. Since network analyses in both specifically determined
EOAD+-genotypes and also in non-specifically, in silico, determined shared genes in EOA, AOA and
dystonia panels both refer to similar underlying pathways, one may hypothesize the presence of a
common pathogenesis. This would implicate that EOAD+-phenotypes can be concurrently induced
by shared genetic networks between EOA and dystonia genes. This could explain the heterogeneous
genotype-phenotype relationships varying from predominant ataxia at one end of the spectrum,
continuing with ataxia and comorbid dystonia, and, finally predominant dystonia at the other end of
the spectrum.
Altogether, in perspective of: (1) the high prevalence of EOAD+ phenotypes, (2) the heterogeneity
of genotype-phenotype relationships, (3) the shared anatomical pathways and (4) the shared underlying
biological pathways that contribute to the same disease continuum, it might be a rationalistic approach
to test EOA patients with a complete, up to date movement disorder panel (including EOA and
dystonia gene lists), instead of with a single EOA gene panel. In the future, we aim to investigate the
pathogenesis of other mixed EOA phenotypes by determining shared pathways between EOA and
other comorbid movement disorders, as well.
5. Conclusions
Comorbid dystonia is prevalent in the majority of EOA patients. The underlying biological
pathways can be linked with energy depletion and hampered signal transduction involving the
cortical-basal-ganglia-pontine-cerebellar network. Hopefully, future insight in the underlying processes
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causing the heterogeneous, mixed EOA phenotypes may contribute to the yield of diagnostic testing
and innovative therapeutic strategies.
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Abbreviations
EOA early onset ataxia
EOAD+ early onset ataxia with dystonic comorbidity
EOAD− early onset ataxia without dystonic comorbidity
TCA tricarboxylic acid cycle
AOA adult onset ataxia
AOAD+ adult onset ataxia with dystonic comorbidity
SCA spino-cerebellar ataxia
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